Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jun 15;27(2):308-324.
doi: 10.11613/BM.2017.034.

Insights on glicentin, a promising peptide of the proglucagon family

Affiliations
Review

Insights on glicentin, a promising peptide of the proglucagon family

Juliette Raffort et al. Biochem Med (Zagreb). .

Abstract

Glicentin is a proglucagon-derived peptide mainly produced in the L-intestinal cells. While the roles of other members of the proglucagon family including glucagon-like peptide 1, glucagon-like peptide 2 and oxyntomodulin has been well studied, the functions and variation of glicentin in human are not fully understood. Experimental and clinical studies have highlighted its role in both intestinal physiology and glucose metabolism, pointing to its potential interest in a wide range of pathological states including gastrointestinal and metabolic disorders. Due to its structure presenting many similarities with the other proglucagon-derived peptides, its measurement is technically challenging. The recent commercialization of specific detection methods has offered new opportunities to go further in the understanding of glicentin physiology. Here we summarize the current knowledge on glicentin biogenesis and physiological roles. In the limelight of clinical studies investigating glicentin variation in human, we discuss future directions for potential applications in clinical practice.

Keywords: enteroendocrine cells; glicentin; glucagon-like peptide; oxyntomodulin; proglucagon.

PubMed Disclaimer

Conflict of interest statement

Potential conflict of interest: None declared.

Figures

Figure 1
Figure 1
Processing of the proglucagon gene into proglucagon-derived peptides (modified from Baggio et al. (4), Holst et al. (5), Bataille et al. (6, 7), Whiting et al. (8)) and DeFronzo et al. (47)). (1) The proglucagon gene is located on the chromosome 2 and is composed of 6 exons and 5 introns. (2) The gene transcription leads to a messenger RNA. (3) The messenger RNA (mRNA) is translated into the proglucagon, a 178 amino-acid precursor protein. (4) Posttranslational processing in the alpha pancreatic cells involves mainly the proconvertase 2 (PC2) and leads to the glicentin related pancreatic polypeptide (GRPP), the glucagon, the intervening peptide-1 (IP-1) and the major proglucagon fragment (MPF). (5) An alternative pathway involving proconvertase 1 and 3 (PC1/3) can lead to glucagon like peptide 1 (GLP-1) formation in the pancreas. (6) In the enteroendocrine L-cells and in the central nervous system, post-translational processing of proglucagon is mediated by proconvertases 1 and 3 and liberates the glicentin, the oxyntomodulin, the glucagon like peptide 1, the Intervening Peptide-2 (IP-2) and the glucagon like peptide 2 (GLP-2). DNA - deoxyribonucleic acid.

Similar articles

Cited by

References

    1. Murphy KG, Bloom SR. Gut hormones and the regulation of energy homeostasis. Nature. 2006;444:854–9. 10.1038/nature05484 - DOI - PubMed
    1. Holst JJ. Enteroendocrine secretion of gut hormones in diabetes, obesity and after bariatric surgery. Curr Opin Pharmacol. 2013;13:983–8. 10.1016/j.coph.2013.09.014 - DOI - PubMed
    1. Sala PC, Torrinhas RS, Giannella-Neto D, Waitzberg DL. Relationship between gut hormones and glucose homeostasis after bariatric surgery. Diabetol Metab Syndr. 2014;6:87. 10.1186/1758-5996-6-87 - DOI - PMC - PubMed
    1. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131–57. 10.1053/j.gastro.2007.03.054 - DOI - PubMed
    1. Holst JJ. Enteroglucagon. Annu Rev Physiol. 1997;59:257–71. 10.1146/annurev.physiol.59.1.257 - DOI - PubMed